Prognosis and feasibility of en-bloc vascular resection in stage II pancreatic adenocarcinoma

Table 1 Clinicopathological features of patients with stage II pancreatic adenocarcinoma (mean ± SD) n (%)

Parameters	With vascular resection (n = 12)	Without vascular resection (n = 75)	P value
Age (yr)	62.9 ± 11.0	62.9 ± 9.8	0.994
Gender			0.745
Male	7 (58.3)	50 (66.7)
Female	5 (41.7)	25 (33.3)
Symptoms
Jaundice	6 (50.0)	55 (73.3)	0.171
Abdominal pain	6 (50.0)	35 (46.7)	0.830
Body weight loss	6 (50.0)	31 (41.3)	0.573
Anorexia	3 (25.0)	17 (22.7)	1.000
Signs
Anemic	4 (33.3)	38 (50.7)	0.265
Icterus	6 (50.0)	54 (72.0)	0.178
Abdominal tenderness	3 (25.0)	15 (20.0)	0.707
Albumin (g/dL)	3.9 ± 0.6	3.7 ± 0.5	0.205
Total bilirubin (mg/dL)	6.8 ± 7.0	8.9 ± 7.1	0.333
Pre-op biliary drainage			0.573
Yes	6 (50.0)	44 (58.7)
No	6 (50.0)	31 (41.3)
CEA (ng/mL)			1.000
≤ 5	5 (62.5)	36 (62.1)
> 5	3 (37.5)	22 (37.9)
CA19-9 (U/mL)			0.411
≤ 37	3 (33.3)	13 (21.0)
> 37	6 (66.7)	49 (79.0)
Operation time (min)	473.9 ± 185.2	461.6 ± 110.4	0.826
Blood transfusion (mL)	396 ± 588	304 ± 590	0.618
Tumor size (cm)	3.6 ± 1.6	3.3 ± 1.4	0.526
Lymph node metastases			0.097
Yes	8 (66.7)	65 (86.7)
No	4 (33.3)	10 (13.3)
Curability			0.015
Yes	12 (100.0)	48 (64.0)
No	0 (0.0)	27 (36.0)
Postoperative chemotherapy			0.436
Yes	8 (66.7)	41 (54.7)
No	4 (33.3)	34 (45.3)

CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen.